Valuation: Ironwood Pharmaceuticals, Inc.

Market Cap 728M 632M 590M 542M 1.02B 69.35B 1.04B 6.96B 2.73B 34.58B 2.73B 2.67B 114B P/E 2026 *
3.73x
P/E 2027 * 3.58x
Enterprise Value 728M 632M 590M 542M 1.02B 69.35B 1.04B 6.96B 2.73B 34.58B 2.73B 2.67B 114B EV / Sales 2026 *
1.58x
EV / Sales 2027 * 1.52x
Free-Float
96.75%
Yield 2026 *
-
Yield 2027 * -
1 day-2.60%
1 week+15.13%
Current month+3.43%
1 month-0.11%
3 months-4.68%
6 months-2.45%
Current year+29.82%
1 week 3.55
Extreme 3.55
4.59
1 month 3.55
Extreme 3.55
4.88
Current year 2.95
Extreme 2.95
5.78
1 year 0.75
Extreme 0.75
5.78
3 years 0.53
Extreme 0.5271
15.7
5 years 0.53
Extreme 0.5271
15.7
10 years 0.53
Extreme 0.5271
21.2
Manager TitleAgeSince
Chief Executive Officer 68 12/03/2021
Director of Finance/CFO 44 15/05/2026
Chief Tech/Sci/R&D Officer - 20/07/2026
Director TitleAgeSince
Director/Board Member 68 04/06/2021
Chairman 61 01/04/2019
Director/Board Member 56 01/04/2019
Date Insider Type Main position Quantity % Market Cap.
20/7/26 Free

Chief Technology Officer

137,036 0.0832%
7/7/26 Sell

Chief Financial Officer

-127,890 0.0777%
23/2/26 Sell

Chief Executive Officer

198,283 0.1219%
Change 5-day change 1-year change 3-year change Capi.($)
-2.83%+15.13%+482.94%-60.69% 728M
+0.50%-3.00%+60.11%+21.78% 316B
+1.61%+0.52%+34.01%-10.27% 71.26B
-0.22%-1.48%+37.04%+93.85% 9.76B
-2.52%-7.68%-4.39%-6.32% 8.4B
-0.76%-4.27%-16.42%-17.04% 4.29B
+0.14%+2.22%-34.69%+5.14% 3.83B
-2.35%-7.01%-14.99%+13.53% 3.5B
-3.36%-6.91%+19.92%+38.07% 2.68B
+0.47%+6.57%+0.22%-2.10% 2.26B
Average -0.90%+1.15%+56.38%+7.59% 42.23B
Weighted average by Cap. +0.54%-1.67%+51.78%+16.69%

Financials

2026 *2027 *
Net sales 460M 400M 373M 343M 646M 43.86B 658M 4.4B 1.72B 21.87B 1.73B 1.69B 72.14B 478M 416M 388M 356M 672M 45.59B 684M 4.58B 1.79B 22.74B 1.8B 1.76B 75B
Net income 182M 158M 147M 135M 255M 17.31B 260M 1.74B 680M 8.63B 682M 667M 28.47B 210M 182M 170M 156M 295M 20B 300M 2.01B 786M 9.98B 788M 771M 32.9B
Net Debt - -
Logo Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc. is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI), and rare diseases. It is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The Company is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.
Employees
100
Date Price Change Volume
05/08/26 USD 4.370 -1.13% 3,194,040
03/08/26 USD 4.420 +4.49% 3,818,188
31/07/26 USD 4.230 +13.40% 3,583,359
30/07/26 USD 3.730 +4.78% 1,299,350
29/07/26 USD 3.560 -6.32% 1,252,812
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
4.420USD
Average target price
6.350USD
Spread / Average Target
+43.67%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IRWD Stock